Brokers Offer Predictions for Apellis Pharmaceuticals, Inc.’s FY2026 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Analysts at Wedbush lowered their FY2026 earnings estimates for shares of Apellis Pharmaceuticals in a report released on Tuesday, May 7th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $4.29 for the year, down from their prior forecast of $4.50. Wedbush currently has a “Neutral” rating and a $57.00 price objective on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.27) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm had revenue of $172.33 million for the quarter, compared to analysts’ expectations of $163.37 million. During the same quarter last year, the firm earned ($1.56) earnings per share. The firm’s revenue for the quarter was up 284.3% compared to the same quarter last year.

A number of other research firms also recently issued reports on APLS. HC Wainwright reissued a “buy” rating and set a $92.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday. Citigroup decreased their price target on shares of Apellis Pharmaceuticals from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday. Oppenheimer boosted their price objective on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $76.67.

Apellis Pharmaceuticals Stock Performance

Apellis Pharmaceuticals stock opened at $42.52 on Thursday. The company has a market cap of $5.16 billion, a price-to-earnings ratio of -12.29 and a beta of 0.97. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $94.75. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. The stock’s 50-day moving average is $53.91 and its 200-day moving average is $57.32.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 1,431 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $96,978.87. Following the completion of the transaction, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at approximately $6,325,516.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Apellis Pharmaceuticals news, insider Adam J. Townsend sold 1,148 shares of Apellis Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $77,799.96. Following the completion of the transaction, the insider now owns 92,453 shares of the company’s stock, valued at $6,265,539.81. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Timothy Eugene Sullivan sold 1,431 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $96,978.87. Following the sale, the chief financial officer now directly owns 93,338 shares in the company, valued at $6,325,516.26. The disclosure for this sale can be found here. Insiders have sold 455,334 shares of company stock valued at $26,511,351 over the last ninety days. Corporate insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of APLS. First Horizon Advisors Inc. grew its holdings in shares of Apellis Pharmaceuticals by 69.0% during the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after purchasing an additional 265 shares during the last quarter. Future Financial Wealth Managment LLC bought a new position in Apellis Pharmaceuticals during the 1st quarter worth $29,000. Covestor Ltd increased its position in Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after buying an additional 677 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Apellis Pharmaceuticals in the first quarter valued at $89,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after acquiring an additional 687 shares during the period. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).